8-K: Outlook Therapeutics Announces Preliminary Results of NORSE EIGHT Trial for Wet AMD Treatment

Outlook Therapeutics' NORSE EIGHT trial for ONS-5010 in wet AMD did not meet its primary endpoint, but showed improvement in vision and a favorable safety profile, with a BLA resubmission planned for early 2025.

Summary

• Outlook Therapeutics announced preliminary topline results from the NORSE EIGHT clinical trial evaluating ONS-5010 for wet age-related macular degeneration (wet AMD).
• The trial did not meet its pre-specified non-inferiority endpoint at week 8, as measured by the mean change in best corrected visual acuity (BCVA).
• The difference in mean BCVA between ONS-5010 and ranibizumab was -2.257 letters, with a 95% confidence interval of (-4.044, -0.470).
• The pre-specified non-inferiority margin was -3.5, and the hypothesis of noninferiority was not met.
• Despite not meeting the primary endpoint, the trial showed a mean improvement of +4.2 letters in BCVA in the ONS-5010 arm and +6.3 letters in the ranibizumab arm.
• ONS-5010 demonstrated a favorable safety profile, with ocular adverse event rates comparable to ranibizumab.
• The company plans to resubmit the Biologics License Application (BLA) for ONS-5010 in the first quarter of calendar 2025 after analyzing the full month 3 data, expected in January 2025.
• Outlook Therapeutics is also planning a potential 2025 launch in the UK and Germany, where LYTENAVA has received marketing authorization.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the trial not meeting its primary endpoint, although there are some positives such as the safety profile and plans for BLA resubmission and European launch. The failure to meet the non-inferiority endpoint is a significant setback.

Positives

• The trial showed an improvement in vision with a mean +4.2 letter improvement in BCVA in the ONS-5010 arm.
• ONS-5010 demonstrated a favorable safety profile, with ocular adverse event rates comparable to ranibizumab.
• Remediation of Chemistry, Manufacturing and Controls (CMC) comments in the Complete Response Letter (CRL) is complete.
• LYTENAVA has already received marketing authorization in the EU and UK.
• The company is planning a potential 2025 launch in the UK and Germany.

Negatives

• The NORSE EIGHT trial did not meet its pre-specified non-inferiority endpoint at week 8.
• The difference in mean BCVA between ONS-5010 and ranibizumab was -2.257 letters, failing to meet the non-inferiority margin of -3.5.
• The p-value of 0.0863 was greater than 0.025, indicating the non-inferiority hypothesis was not met.

Risks

• The failure to meet the primary endpoint in the NORSE EIGHT trial could impact the FDA's decision on the BLA resubmission.
• There are risks associated with developing and commercializing pharmaceutical product candidates, including obtaining necessary regulatory approvals.
• The company's future success depends on the sufficiency of its cash resources.
• Market conditions and macroeconomic factors, such as ongoing overseas conflicts, high interest rates, and inflation, could impact the company's business.

Future Outlook

Outlook Therapeutics plans to resubmit the BLA for ONS-5010 in the first quarter of calendar 2025 and is also planning a potential 2025 launch in the UK and Germany. The company is also exploring licensing partnerships for markets outside of the United States.

Management Comments

• Outlook Therapeutics remains confident that ONS-5010/ LYTENAVA is an important therapy for the treatment of wet AMD in place of off-label repackaged bevacizumab.
• The company is working to initiate its commercial launch of LYTENAVA in the EU and the UK as a treatment for wet AMD, expected in the first half of calendar 2025.

Industry Context

This announcement is significant as it provides an update on the clinical development of ONS-5010, a potential alternative to off-label bevacizumab for wet AMD. The results will be closely watched by competitors and investors in the ophthalmology space, particularly those focused on treatments for retinal diseases.

Comparison to Industry Standards

• The NORSE EIGHT trial compared ONS-5010 to ranibizumab, a standard treatment for wet AMD.
• While ranibizumab achieved a +6.3 letter improvement in BCVA, ONS-5010 only achieved a +4.2 letter improvement, failing to meet the non-inferiority endpoint.
• Other companies such as Regeneron (Eylea) and Roche (Lucentis) also have approved treatments for wet AMD, and the results of this trial will be compared to their efficacy and safety data.
• The failure to meet the non-inferiority endpoint is a setback for ONS-5010, as it needs to demonstrate comparable efficacy to existing treatments to gain market share.

Stakeholder Impact

• Shareholders may react negatively to the news of the trial not meeting its primary endpoint.
• Patients with wet AMD may have to wait longer for a potential new treatment option.
• Employees may be impacted by the company's future performance and strategic decisions.
• Potential licensing partners may re-evaluate their interest in the company.

Next Steps

• Complete analysis of the month 3 data from the NORSE EIGHT trial, expected in January 2025.
• Resubmit the Biologics License Application (BLA) for ONS-5010 in the first quarter of calendar 2025.
• Continue planning for a potential 2025 launch in the UK and Germany.
• Continue discussions with potential licensing partners for markets outside of the United States.

Key Dates

Keywords

ONS-5010, LYTENAVA, wet AMD, NORSE EIGHT, clinical trial, bevacizumab, BLA, FDA, non-inferiority, BCVA, retina, ophthalmic